HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Red and blue arrow elevators with businessmen going up and down.

HIV market stalwart Gilead Sciences Inc. is once again positioned for huge success with its recently launched single-tablet regimen Biktarvy (BIC/F/TAF), but competitor ViiV Healthcare still could emerge as the market leader over the next decade, Datamonitor Healthcare analysts conclude.

The US FDA approved Gilead's Biktarvy, which combines the integrase inhibitor bictegravir, the nucleoside reverse transcriptase inhibitorEmtriva (emtricitabine) and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Market Snapshot

More from Scrip